氟哌噻吨美利曲辛治疗胃溃疡伴抑郁症的疗效

目的探讨分析氟哌噻吨美利曲辛治疗胃溃疡伴抑郁症的疗效。方法选取我院2011年3月至2012年3月问收治的62例胃溃疡伴抑郁症患者,随机分为观察组和对照组,每组患者各31例。观察组患者在常规药物治疗的基础上,给予氟哌噻吨美利曲辛治疗。对照组患者仅给予常规药物治疗。观察比较两组患者治疗后的疗效、HAMD评分、不良反应发生情况。结果观察组患者的总有效率为93．55％,对照组患者的总有效率为80．65％,两组比较差异有统计学意义俨〈0．05）。两组均无明显不良反应发生。结论氟哌噻吨美利曲辛治疗胃溃疡伴抑郁症的疗效显著,值得临床推广。     

氟哌噻吨美利曲辛治疗胃溃疡伴抑郁症的临床疗效

目的：观察氟哌噻吨美利曲辛治疗伴有抑郁症的胃溃疡患者的临床疗效。方法选取2013年3月～2013年10月胃溃疡伴抑郁症患者90例作为研究对象,并将所有患者随机分为对照组和治疗组,对照组患者使用常规药物治疗,治疗组患者在使用常规治疗药物的基础上联合应用氟哌噻吨美利曲辛治疗。4周后观察两组患者治疗后的胃溃疡情况及Hamiltion抑郁量表（HAMD）评分情况。结果4周后,对照组总有效率为87.78%,治疗组总有效率为96.67%,两组比较差异具有统计学意义（P＜0.05）;两组治疗后的HAMD评分均下降,但治疗组评分下降程度明显大于对照组,两组比较差异具有统计学意义（P＜0.05）;两组均无明显的不良反应。结论联用氟哌噻吨美利曲辛治疗伴有抑郁症的胃溃疡患者疗效优于常规药物治疗,具有很好的临床使用价值。     

氟哌噻吨美利曲辛治疗脑梗死后抑郁症的疗效观察

目的:观察氟哌噻吨美利曲辛对脑梗死后抑郁症的治疗效果.方法:筛选脑梗死后抑郁症患者60例,随机分为两组(治疗组和对照组),每组30例.在采用神经内科常规治疗基础上,治疗组给予氟哌噻吨美利曲辛治疗.对照组给予心理疏导.评价指标选用汉密尔顿抑郁评分、神经功能缺损程度评分.结果:治疗6周时抑郁症评价指标及神经功能缺损程度治疗组与对照组相比改善明显(P<0.01),具有显著差异,治疗3周时神经功能缺损程度及抑郁程度两组差别不明显(P>0.05),6周时治疗组与对照组比较明显改善(P<0.05),差异具有统计学意义.结论:氟哌噻吨美利曲辛治疗脑梗死后抑郁症具有较好疗效,能够减轻抑郁,促进神经功能缺损恢复,提高生活质量,不良反应少,反应轻,患者能够耐受,值得在临床推广.     

氟哌噻吨美利曲辛治疗胃溃疡并发抑郁症36例

目的 研究氟哌噻吨美利曲辛对于胃溃疡伴抑郁症患者的临床疗效分析.方法72例胃溃疡并发抑郁症患者,按照严格随机分组原则分为治疗组与对照组各36例.所有患者均给予质子泵抑制药、胃黏膜保护药、抗幽门螺杆菌治疗,治疗组在上述基础上给予氟哌噻吨美利曲辛,10.5 mg.d^-1.比较患者症状评分、汉密尔顿抑郁量表评分、不良反应、疗效等.结果治疗后两组患者症状评分均有所改善,但治疗组比对照组患者症状平均积分减少更加明显,且其汉密尔顿抑郁量表评分较治疗前明显降低(P<0.05);对照组患者的治愈率为72.2%(26/36),治疗组治愈率为88.9%(32/36);两组均未见明显不良反应.结论常规治疗联合氟哌噻吨美利曲辛对于胃溃疡伴抑郁症患者的治疗效果显著,不良反应少,患者肠胃功能恢复快,能显著提高患者精神、生活质量,具有较高的临床研究价值.     

氟哌噻吨美利曲辛治疗胃溃疡伴抑郁症的临床效果

目的 研究氟哌噻吨美利曲辛治疗胃溃疡伴抑郁症的临床效果。方法 96例胃溃疡伴抑郁症患者,随机分为对照组和观察组,各48例,对照组采取胃溃疡常规药物治疗,观察组在常规药物治疗基础上服用氟哌噻吨美利曲辛。对比两组治疗效果。结果 采用不同药物治疗之后,研究发现对照组患者总有效率为85.4%,观察组患者总有效率为93.8%,观察组患者抑郁量表评分降低幅度大于对照组,差异有统计学意义(P<0.05),两组患者治疗后不良反应差异无统计学意义(P>0.05)。结论 在常规药物治疗基础上使用氟哌噻吨美利曲辛治疗方法 ,在胃溃疡伴抑郁症治疗中能够有效减轻患者的抑郁症状,提高治疗效果,可在临床中推广。     

胃溃疡伴抑郁症采用氟哌噻吨美利曲辛治疗的临床价值分析

目的分析探讨胃溃疡伴抑郁症行氟哌噻吨美利曲辛治疗的临床效果。方法选取我院近年来收治的94例胃溃疡伴抑郁症患者作为研究对象,按照患者治疗方法将其分为研究组与对照组,每组47例,研究组在常规治疗的基础上行氟哌噻吨美利曲辛治疗,对照组患者行常规治疗,比较两组患者病症改善效果。结果研究组治疗总有效率为95.8%,治愈率为51.1%,对照组患者治疗总有效率为80.9%,治愈率为29.8%,组间比较差异有统计学意义(P<0.05);研究组患者抑郁状况改善效果明显优于对照组(P<0.05);两组治疗期间不良反应发生率无显著差异(P>0.05)。结论对胃溃疡伴抑郁症患者行氟哌噻吨美利曲辛治疗能够改善患者溃疡病症,缓解患者的抑郁症状,应用效果十分显著,可以进行推广应用。     

氟哌噻吨美利曲辛治疗卒中后抑郁症

目的 :评价氟哌噻吨 美利曲辛治疗卒中后抑郁症的疗效和安全性。方法 :将 10 7例卒中后抑郁症病人随机分为治疗组 54例用氟哌噻吨 美利曲辛每日 2～ 4片 ,po ;对照组 53例用阿米替林 2 5～ 50mg ,po ,tid ,疗程均为 6wk。采用HAMD ,HAMA及CGI和TESS评定疗效和药物不良反应。结果 :治疗 6wk末 ,HAMD ,HAMA及CGI总分均显著下降 (P <0 .0 1)。氟哌噻吨 美利曲辛和阿米替林的总有效率分别为 95%和 96 % (P >0 .0 5)。该药的不良反应显著低于阿米替林 (P <0 .0 1)。结论 :氟哌噻吨 美利曲辛治疗卒中后抑郁症安全、有效     

胃溃疡伴抑郁症采用氟哌噻吨美利曲辛治疗的临床效果分析

目的:探讨胃溃疡伴抑郁症采用氟哌噻吨美利曲辛治疗的临床效果。方法:以2012年1月~2014年1月之间在某院接受治疗的100例胃溃疡伴抑郁症患者为观察对象,随机将其分为对照组和实验组,对照组接受奥美拉唑治疗,实验组接受氟哌噻吨美利曲辛治疗,对比分析两组观察对象的临床治疗效果。结果:实验组观察对象临床治疗总有效率明显高于对对照组(P0.05),且临床治疗后HAMD评分结果优于对照组(P0.05),两组观察对象临床治疗后不良反应发生情况对比无统计学差异(P0.05)。结论:本次医学研究结果证实,胃溃疡伴抑郁症患者接受氟哌噻吨美利曲辛治疗,有助于患者治疗效果的巩固,以及神经状态的恢复,因而临床推广应用价值较高。     

氟哌噻吨美利曲辛片治疗胃溃疡伴抑郁症的临床疗效观察

目的：探讨氟哌噻吨美利曲辛片治疗胃溃疡伴抑郁症的临床效果。方法选择2011年11月—2013年11月我院收治的82例胃溃疡伴抑郁症患者,随机分为对照组和治疗组,每组41例。对照组应用质子泵抑制剂类、胃黏膜保护剂类、抗幽门螺杆菌类药物实施常规治疗;治疗组在对照组用药基础上口服氟哌噻吨美利曲辛片。比较两组患者心理状态恢复正常时间、胃溃疡症状消失时间、住院时间、药物不良反应、胃溃疡合并抑郁症病情治疗效果。结果对照组心理状态恢复正常时间、胃溃疡症状消失时间、住院时间分别为（13.0±2.4）d、（7.6±1.6）d、（15.6±2.4）d,长于治疗组的（9.0±1.6）d、（5.0±0.7）d、（11.5±2.6）d,差异均有统计学意义（P〈0.05）。治疗组的总有效率为90.3%,高于对照组的68.2%,差异有统计学意义（ P〈0.05）。对照组患者中出现不良反应9例（22.0%）,治疗组中出现不良反应1例（2.4%）,对照组不良反应发生率高于治疗组,差异有统计学意义（ P〈0.05）。结论氟哌噻吨美利曲辛片治疗胃溃疡伴抑郁症的疗效确切,不良反应少,临床实际应用安全有效。     

氟哌噻吨/美利曲辛治疗老年脑卒中后抑郁症疗效观察

目的观察氟哌噻吨/美利曲辛治疗脑卒中后抑郁症的临床疗效和不良反应。方法 80例脑卒中后抑郁症患者随机分为2组,治疗组40例予氟哌噻吨/美利曲辛治疗;对照组40例予度洛西汀、劳拉西泮治疗。2组均连续服用3周。采用汉密顿抑郁量表(HAMD-17项)、神经功能缺损评分表(NIHSS)评定疗效,副反应量表(TESS)评定药物的不良反应。结果治疗组总有效率为87.5%,对照组为85.0%,差异无统计学意义(P>0.05)。2组治疗后HAMD、NIHSS评分均逐渐减低,治疗6周后均较治疗前显著下降(P<0.05),组间同期比较差异均无统计学意义(P>0.05)。2组TESS评分的比较差异有统计学意义(P<0.05)。结论氟哌噻吨/美利曲辛治疗脑卒中后抑郁疗效确切,不良反应较少。     

氟哌噻吨美利曲辛片治疗功能性消化不良的临床研究

目的评价氟哌噻吨美利曲辛片(黛力新)联合质子泵抑制剂及促胃动力药治疗功能性消化不良伴焦虑抑郁症患者的近期疗效及不良反应。方法将88例功能性消化不良伴焦虑抑郁症患者随机分为两组,对照组28例予以雷贝拉唑及多潘立酮治疗;实验组60例在对照组治疗基础上加用黛力新,共治疗4周。观察治疗前后胃肠道症状评定量表(GSRS)、医院焦虑抑郁量表(HADS)的评分变化及不良反应。结果两组治疗前GSRS及HADS评分比较,差异无统计学意义(P>0.05),治疗4周后,实验组GSRS及HADS评分较对照组降低,差异有统计学意义(P=0.000)。实验组显效30例(50.0%),有效28例(46.7%),无效2例(3.3%),总有效率为96.7%;对照组显效0例(0.0%),有效10例(35.7%),无效18例(64.3%),总有效率为35.7%。实验组的总有效率较对照组高,差异有统计学意义(P=0.000)。88例患者均无严重不良反应发生。结论黛力新联合质子泵抑制剂及促胃动力药治疗功能性消化不良伴焦虑抑郁症的近期疗效显著,且无明显不良反应,值得临床推广应用。     

Desvenlafaxine in the treatment of major depressive disorder

Desvenlafaxine (DESV) is a newer antidepressant, which inhibits serotonin-norepinephrine reuptake neurotransmission, similarly to venlafaxine, milnacipran and duloxetine. It was approved in February 2008 by the FDA for the treatment of major depressive disorder (MDD), based on well-controlled and adequately powered, large clinical trials demonstrating efficacy and safety for patients with MDD. Currently available data show that DESV has proven efficacy, acceptable safety and tolerability profiles, convenient once-daily dosing and minimal impact on the cytochrome P450 enzyme system in patients with MDD. This mini-review summarizes the clinical data and practical use of DESV under this approved indication.     

Desvenlafaxine in the treatment of major depressive disorder

Desvenlafaxine (DESV) is a newer antidepressant, which inhibits serotonin-norepinephrine reuptake neurotransmission, similarly to venlafaxine, milnacipran and duloxetine. It was approved in February 2008 by the FDA for the treatment of major depressive disorder (MDD), based on well-controlled and adequately powered, large clinical trials demonstrating efficacy and safety for patients with MDD. Currently available data show that DESV has proven efficacy, acceptable safety and tolerability profiles, convenient once-daily dosing and minimal impact on the cytochrome P450 enzyme system in patients with MDD. This mini-review summarizes the clinical data and practical use of DESV under this approved indication.     

Paroxetine treatment of major depressive disorder

Major depression is recognized as a common, often chronic and recurrent illness that is associated with significant disability and comorbidity. The treatment of patients with major depressive disorder has advanced tremendously in the past decade as a result of the availability of effective and well-tolerated antidepressants. Paroxetine is a widely studied selective serotonin reuptake inhibitor (SSRI) with evidence for efficacy and safety that is supported by a large body of published literature. Evidence for the efficacy and tolerability of anew controlled-release formulation of paroxetine also has been published. Findings from paroxetine clinical studies have added considerably to our knowledge and understanding of the treatment of major depressive disorder, particularly with regard to duration of treatment, the need for treating to full remission and with full doses, and treatment of patients with concurrent symptoms of anxiety.     

Agomelatine for the treatment of major depressive disorder

INTRODUCTION: This article discusses agomelatine (Valdoxan(?)/Thymanax(?); Servier/Novartis), which is a melatonin (MT1/MT2) agonist and serotonin (5-HT2c) receptor antagonist. Agomelatine has been approved for the treatment of adults with major depression by several regulatory agencies and is now on the market in 41 countries. AREAS COVERED: Literature related to agomelatine was reviewed on PubMed using the search terms 'agomelatine OR S-20098' and 204 articles were found. Twelve published, randomized, double-blind studies were included in this review. EXPERT OPINION: Agomelatine produces strong effects on circadian sleep phase disturbances, improving time to sleep onset and quality of sleep. It has been shown to be superior to placebo and similar to existing antidepressants, as demonstrated by short-term clinical trials and one relapse prevention trial. However, 0 - 0.6% and 3 - 4.5% of patients treated with 25 and 50 mg, respectively, showed elevated transaminases. Although none of these reactions so far seem to have been serious, the adverse effects in the liver may present a regulatory and marketing challenge. Given equivalence or modest superiority to existing, generic alternatives, the acceptability in a third-party reimbursement environment is questionable. Future clinical trials are needed to establish an appropriate market niche.     

Desvenlafaxine for the treatment of major depressive disorder

Introduction: Major depressive disorder (MDD) is a chronic and debilitating condition often characterized by inadequate treatment. Notwithstanding the availability of more than a dozen first-line agents across disparate classes (e.g., selective serotonin reuptake inhibitors), the majority of individuals with MDD do not achieve and sustain a recovered state. A substantial percentage of MDD patients require a treatment change due to poor efficacy or tolerability.

Areas covered: This review focuses on recent (≤ 5 years) literature describing the pharmacokinetics, efficacy, and tolerability of desvenlafaxine, one of the more recently approved antidepressant drugs. Published papers identified via PubMed search and congress presentations were included. Results from short-term, placebo-controlled, MDD trials and randomized withdrawal trials, as well as post hoc analyses in patient subgroups, are reviewed.

Expert opinion: Desvenlafaxine has been shown to be an effective antidepressant with a favorable safety and tolerability profile in the general MDD population and in important patient subgroups. It has several notable differences from other serotonin-norepinephrine reuptake inhibitors, and those differences suggest populations in which it may have the most clinical benefit.     

Vortioxetine for the treatment of major depressive disorder

Vortioxetine (Brintellix^®, 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT_1A, 5-HT_1B, 5-HT_1D, 5-HT₃, 5-HT₇ receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine administration induces antidepressant- and anxiolytic-like effects, and can enhance cognitive performance in rodents. Several clinical trials have reported the efficiency and a satisfactory tolerability of vortioxetine treatment in depressed patients. Remarkably, vortioxetine has a specific positive impact on cognitive symptoms in depressed patients. Overall, vortioxetine is an efficacious antidepressant drug for the treatment of patients with a major depressive episode and has a unique mechanism of action offering a new therapeutic option.     

Duloxetine for the treatment of major depressive disorder

>55% were observed in two of the studies, while in a third study the probability of remission with duloxetine treatment was nearly three times that observed with placebo (44% versus 16%). Duloxetine also produced significant improvement in painful physical symptoms compared with placebo, in many cases after only 2 weeks of treatment. The discontinuation rate due to adverse events (14.6%) was similar to those observed with selective serotonin reuptake inhibitors. The most frequently reported adverse events were nausea, dry mouth, fatigue, and insomnia. Conclusion. Duloxetine was demonstrated to be safe and effective in the treatment of MDD. The starting dose with the best balance of efficacy and tolerability is 60 mg QD.     

Agomelatine for the treatment of major depressive disorder

Introduction: This article discusses agomelatine (Valdoxan^?/Thymanax^?; Servier/Novartis), which is a melatonin (MT1/MT2) agonist and serotonin (5-HT2c) receptor antagonist. Agomelatine has been approved for the treatment of adults with major depression by several regulatory agencies and is now on the market in 41 countries.

Areas covered: Literature related to agomelatine was reviewed on PubMed using the search terms ‘agomelatine OR S-20098’ and 204 articles were found. Twelve published, randomized, double-blind studies were included in this review.

Expert opinion: Agomelatine produces strong effects on circadian sleep phase disturbances, improving time to sleep onset and quality of sleep. It has been shown to be superior to placebo and similar to existing antidepressants, as demonstrated by short-term clinical trials and one relapse prevention trial. However, 0 – 0.6% and 3 – 4.5% of patients treated with 25 and 50 mg, respectively, showed elevated transaminases. Although none of these reactions so far seem to have been serious, the adverse effects in the liver may present a regulatory and marketing challenge. Given equivalence or modest superiority to existing, generic alternatives, the acceptability in a third-party reimbursement environment is questionable. Future clinical trials are needed to establish an appropriate market niche.